SOURCE: MMIT Analytics, as of 11/21/19
Monday, November 25, 2019
The FDA last week approved...
...Pfizer's Abrilada, the fifth biosimilar to AbbVie's Humira set
to hit the market when the company's US patent expires in 2023. For the
treatment of rheumatoid arthritis in the pharmacy benefit, Humira holds
preferred formulary status for 8% of covered lives, growing to 61% with prior
authorization and/or step therapy.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment